- Supported exchanges /
- F /
- 47N.F
CITIUS PHARMAC. DL -001 (47N F) stock market data APIs
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
CITIUS PHARMAC. DL -001 Financial Data Overview
| 0.3024 | |
| 0.3024 | |
| - | |
| 0.3024 | |
| 0.3024 | |
| 0.2792-0.933 | |
| 60 739 K | |
| 181 M | |
| 0 | |
| -0.06 | |
| 1.611 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
CITIUS PHARMAC. DL -001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -41 067 916
- Earnings Per Share -0.22
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get CITIUS PHARMAC. DL -001 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.06
Get CITIUS PHARMAC. DL -001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
